FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive DisorderBusiness Wire • 03/22/23
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its StockBusiness Wire • 03/14/23
Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory BoardBusiness Wire • 02/28/23
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 ForumBusiness Wire • 02/21/23
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol MisuseBusiness Wire • 02/14/23
FSD Pharma receives regulatory clearance for proposed Phase 1 clinical trial of multiple sclerosis drug candidate Lucid-MSProactive Investors • 02/07/23
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug CandidateBusiness Wire • 02/07/23
FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCASProactive Investors • 01/30/23
Recruiting Underway in FSD Pharma's Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)Business Wire • 01/30/23
FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MSProactive Investors • 01/17/23
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigationBusiness Wire • 01/17/23
FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reservesProactive Investors • 01/13/23
FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in AustraliaProactive Investors • 01/09/23
FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in AustraliaBusiness Wire • 01/09/23
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza BokhariBusiness Wire • 11/10/22
FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation AvailableBusiness Wire • 09/12/22
FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorderProactive Investors • 09/06/22
FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation SyndromeBusiness Wire • 09/06/22
FSD Pharma says Lucid Psycheceuticals subsidiary files patent for novel PEA formulations; presents preclinical toxicology results at international symposiumProactive Investors • 07/13/22